{"extracted_data":{"metadata":{"version":"1.0","description":"RWE Studies Annotations for Extraction Task","created_at":"2025-03-22T18:12"},"raw_data":{"populations":[{"stage_histology":"Stage IIIB/IVA, adenocarcinoma","pdl1_status":"PD-L1 negative","n":80},{"n":171,"stage_histology":"Stage IVB, adenocarcinoma","pdl1_status":"PD-L1 negative"},{"stage_histology":"Stage IIIB/IVA, squamous","pdl1_status":"PD-L1 positive/high","n":51},{"stage_histology":"Stage IVB, squamous","pdl1_status":"PD-L1 positive/high","n":37}],"results":{"os_12_month":"52.2%","treatment_specific_results":{"first-line pembrolizumab plus platinum-based chemotherapy":{"median_os":"12.7 months","median_pfs":"8.0 months"}},"group_difference":"p D0.001 for number of metastatic sites","median_os":"12.7 months","median_rw_pfs":"8.0 months","median_pfs":"8.0 months"},"treatment_regimens":["first-line pembrolizumab plus platinum-based chemotherapy"],"countries":["UK","Switzerland"]},"study_name":"Study from Banna 2022.pdf","file_name":"Banna 2022.pdf"},"status":"success","_timestamp":1.742663532446499e+09,"_runtime":9.955517,"_step":0,"_wandb":{"runtime":9},"study_name":"Study from Banna 2022.pdf"}